Eisai (4523) Stock Overview

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

4523 Stock Information

Symbol

4523

Address

4-6-10, KoishikawaTokyo, 112-8088Japan

Founded

Trading hours

Website

https://www.eisai.co.jp

Country

🇯🇵 Japan

Phone Number

81 3 3817 3700

Eisai (4523) Price Chart

Eisai Overview: Key Details and Summary

Stock data	2023	Change
Price	$42.21	N/A
Market Cap	$12.10B	N/A
Shares Outstanding	286.76M	0.03%
Employees	11.08K	N/A
Shareholder Equity	822.57B	6.62%

Valuation	2023	Change
P/E Ratio	0.22	N/A
P/S Ratio	2.35	N/A
P/B Ratio	0.01	N/A

Growth	2023	Change
Return on Equity	0.0005	N/A

Earnings	2023	Change
Revenue	$5.15B	N/A
Earnings	$393.41M	N/A
EPS	193.31	N/A
Earnings Yield	4.58	N/A
Gross Margin	0.7611	N/A
Operating Margin	0.0538	N/A
Net income margin	0.0764	N/A

Financial Strength	2023	Change
Total Assets	$8.74B	N/A
Total Debt	$872.88M	N/A
Cash on Hand	$1.85B	N/A
Debt to Equity	0.0037	-11.62%
Cash to Debt	$2.12	-34.99%
Current Ratio	$2.08	1.80%